Company news

Nektar Therapeutics news in 2023

Nektar Therapeutics's news releases, calls and decks from 2023, newest first.

View company

Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting

December 10, 2023

Nektar Therapeutics Reports Third Quarter 2023 Financial Results

November 6, 2023

Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets

October 30, 2023

Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

October 12, 2023

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

October 1, 2023

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

September 26, 2023

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

September 12, 2023

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th

September 5, 2023

Nektar Therapeutics Reports Second Quarter 2023 Financial Results

August 7, 2023

Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

August 6, 2023

Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets

July 31, 2023

Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

June 11, 2023

Nektar Therapeutics Reports First Quarter 2023 Financial Results

May 8, 2023

Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development

April 26, 2023

Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan

April 16, 2023

Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank

March 10, 2023

Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results

February 27, 2023

Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus

February 22, 2023

Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA

January 3, 2023

Calls in 2023

Decks in 2023